多年来，迪瑞医疗研发坚持以市场化为导向，围绕创新驱动发展，七大产品线协同发力，在检测系统、 智能检测、智能诊断领域不断探索创新，持续保持技术升级带动产品更新迭代。为顺应当前医疗产业智 能化趋势，以多年积累的仪器产品研发经验为依托、以提升产品智能化水平为目标，在尿液分析领域， 基于人工智能+湿化学染色技术，以深度学习技术为核心，构建了针对流式细胞显微图像的智能识别系 统。该系统采用多层卷积神经网络（CNN）架构，通过数十万份标注清晰的临床尿液样本图像进行模 型训练，涵盖了红细胞、白细胞、管型、尿路上皮细胞、细菌、非典型细胞等临床病理成分，通过训练 好的参数对各类有形成分进行分类预测。为解决医学图像小样本、类别不平衡问题，创新性地引入迁移 学习与数据增强技术，结合自注意力机制优化模型对微弱病理特征的捕捉能力，使模型对管型、菌丝等 低频次出现、极具病理意义的成分也有很好的识别能力，目前已应用在FUS系列产品中，推动尿液分析 从经验依赖型向算法驱动型转变。 公开资料显示，迪瑞医疗发布2025年三季度报告。报告显示，前三季度公司营业收入4.69亿元，同步下 降60.12%；归属于上市公司股东的净利润为-8，725万元， ...

Group 1 - The application of AI in the healthcare sector is accelerating, driven by advancements in information technology and artificial intelligence, leading to significant transformations in the industry [1] - Di Rui Medical (300396) has over 30 years of experience in the IVD field, focusing on seven major product lines, and is optimizing its R&D efforts to enhance product intelligence in line with the trend of medical industry automation [1][3] - The company is leveraging AI technology to improve diagnostic accuracy and treatment effectiveness, particularly in areas such as auxiliary diagnosis, personalized treatment, and drug development [1] Group 2 - Di Rui Medical has developed an AI-based automatic recognition system for urinary components, utilizing deep learning and a multi-layer convolutional neural network (CNN) architecture trained on a large dataset of clinical urine sample images [2] - The system addresses challenges such as small sample sizes and class imbalance in medical imaging by incorporating transfer learning and data augmentation techniques, enhancing the model's ability to identify rare but clinically significant pathological features [2] - This technology is implemented in the FUS series products, facilitating a shift from experience-based to algorithm-driven urinary analysis, thereby supporting early screening for kidney diseases [2] Group 3 - To enhance market competitiveness, Di Rui Medical is employing multi-modal AI large model algorithms to integrate laboratory test results with various patient data for comprehensive diagnostic support, aiming to reduce misdiagnosis and improve diagnostic efficiency [3] - The company is under the control of China Resources Limited, which has been enhancing its management model since November 2020, with plans to strengthen the company's role as the sole medical device platform within the China Resources system by 2025 [3] - Di Rui Medical reported a revenue of 1.218 billion yuan for 2024, a decrease of 11.63% year-on-year, and a net profit of 142 million yuan, down 48.50% from the previous year, with a dynamic P/E ratio of approximately 17, below the industry average of 34 [3]